Dealwatch: Big-ticket life sciences activity picks up again as overseas investors buy into the UK

The broader life sciences sector saw a spate of deal activity in recent weeks, with two acquisitions over the billion-dollar mark and several more in the hundreds of millions.

The highest-value transaction came on 28 August, when US-based life sciences company Danaher announced its agreement to purchase Cambridge-based protein research tools supplier Abcam in a deal valued at $5.7bn.

Your limit of 1 article in 30 days is up. Please login for full access or subscribe.